ReviewBone marrow transplantation2005
Immune restoration following hematopoietic stem cell transplantation: an evolving target.
Review in Bone marrow transplantation, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 114 citations in OpenAlex.
- BK polyomavirus reactivation after reduced-intensity double umbilical cord blood cell transplantation.Transplant immunology · 2015Trial
- Comparison of immune recovery in recipients of unmanipulated vs T-cell-depleted grafts from unrelated donors in a multicenter randomized phase II-III trial (T-cell depletion trial).Bone marrow transplantation · 2010Trial
- Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11).BMC medicine · 2009Trial
- Time-dependent immune and skeletal alterations following total-body irradiation and hematopoietic stem cell transplantation in a murine arthritis model.Frontiers in immunology · 2026Article
- RUNX1-IT1 and AK026392.1 long non-coding RNAs as early predictors of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in acute leukemia.Caspian journal of internal medicine · 2026Article
- Impact of post-transplant cyclophosphamide and anti-thymocyte globulin on immune reconstitution in MUD allo-HCT.Frontiers in immunology · 2026Observational
- Hematopoietic stem cells and HSCs-derived from pluripotent stem cells: a hopeful outlook in cell-based therapeutics.Molecular biology reports · 2025Review
- Stem cell therapies: a new era in the treatment of multiple sclerosis.Frontiers in neurology · 2024Review
- Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.Molecular cancer · 2023Review
- Expansion of large granular lymphocytes after autologous hematopoietic stem cell transplantation.International journal of hematology · 2023Article
- Graft-versus-host disease: teaching old drugs new tricks at less cost.Frontiers in immunology · 2023Review
- Immune reconstitution and survival of patients after allogeneic hematopoietic stem cell transplantation from older donors.Clinical transplantation · 2023Article
- Are homeostatic mechanisms aiding the reconstitution of the T-cell pool during lymphopenia in humans?Frontiers in immunology · 2022Review
- Lung Microbiota Signature and Corticosteroid Responses in Pneumonia-Associated Acute Respiratory Distress Syndrome in Hematological Patients.Journal of inflammation research · 2022Article
- Stem Cell Therapy as a Treatment for Autoimmune Disease-Updates in Lupus, Scleroderma, and Multiple Sclerosis.Current allergy and asthma reports · 2021Review
- Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus.Current hematologic malignancy reports · 2019Review
- Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2017Article
- Recovery of mucosal-associated invariant T cells after myeloablative chemotherapy and autologous peripheral blood stem cell transplantation.Clinical and experimental medicine · 2016Article
- Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2016Review
- Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid.BMC pharmacology & toxicology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Hematopoietic stem cell transplantation (HSCT) is the definitive cure for many malignant and nonmalignant diseases. However, delays in immune reconstitution (IR) following HSCT significantly limit the success of transplantation and increase the risk for infection and disease relapse in the transplant recipient. Therefore, ways to measure and to manipulate immune recovery following HSCT are emerging and their success depends directly upon an enhanced understanding for the underlying mechanisms responsible for reconstituted immunity and hematopoiesis. Recent discoveries in the activation, function, and regulation of dendritic cell (DC), natural killer (NK) cell, and T-lymphocyte subtypes have been critical in developing immunotherapies used to prevent graft-versus-host disease and to enhance graft-versus-leukemia. For example, regulatory T cells that induce tolerance and NK receptor-tumor ligand disparities that result in tumor lysis are being used to minimize GVHD and tumor burden, respectively. Furthermore, expansion and modulation of immune effector cells are being used to augment hematopoietic and immune recovery and to decrease transplant-related toxicity in the transplant recipient. Specifically, DC expansion and incorporation into antitumor and anti-microbial vaccines is fast approaching application into clinical trials. This paper will review our current understanding for IR following HSCT and the novel ways in which to restore immune function and decrease transplant-related toxicity in the transplant recipient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.